- Home
- BTE vs HCM Comparison
BTE vs HCM Comparison
Compare BTE & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTE | HCM |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | Canada | Hong Kong |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BTE | HCM |
|---|---|---|
| Price | $3.39 | $14.50 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | ★ 18.9M | 45.8K |
| Earning Date | 03-04-2026 | 03-18-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.20 | ★ 0.53 |
| Revenue | ★ $2,194,819,404.00 | $602,197,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.54 |
| P/E Ratio | $17.26 | ★ $5.43 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.36 | $11.51 |
| 52 Week High | $3.63 | $19.50 |
Technical Indicators
Market Signals| Indicator | BTE | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 49.55 |
| Support Level | $3.36 | $14.33 |
| Resistance Level | $3.57 | $14.99 |
| Average True Range (ATR) | 0.13 | 0.36 |
| MACD | -0.00 | -0.13 |
| Stochastic Oscillator | 55.42 | 33.52 |
Price Performance
Historical ComparisonAbout BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.